Immix Ev To Free Cash Flow from 2010 to 2024

IMMX Stock  USD 2.29  0.19  9.05%   
Immix Biopharma EV To Free Cash Flow yearly trend continues to be fairly stable with very little volatility. EV To Free Cash Flow will likely drop to -9.42 in 2024. EV To Free Cash Flow is a valuation metric comparing Immix Biopharma's enterprise value to its free cash flow, used to evaluate whether Immix Biopharma is undervalued or overvalued. View All Fundamentals
 
EV To Free Cash Flow  
First Reported
2010-12-31
Previous Quarter
(8.97)
Current Value
(9.42)
Quarterly Volatility
17.09615304
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immix Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immix Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 12.5 K, Net Interest Income of 360.6 K or Depreciation And Amortization of 3 K, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 7.68 or Book Value Per Share of 0.98. Immix financial statements analysis is a perfect complement when working with Immix Biopharma Valuation or Volatility modules.
  
Check out the analysis of Immix Biopharma Correlation against competitors.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Latest Immix Biopharma's Ev To Free Cash Flow Growth Pattern

Below is the plot of the Ev To Free Cash Flow of Immix Biopharma over the last few years. It is a valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued. Immix Biopharma's EV To Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immix Biopharma's overall financial position and show how it may be relating to other accounts over time.
Ev To Free Cash Flow10 Years Trend
Very volatile
   Ev To Free Cash Flow   
       Timeline  

Immix Ev To Free Cash Flow Regression Statistics

Arithmetic Mean(21.10)
Coefficient Of Variation(81.04)
Mean Deviation7.81
Median(19.76)
Standard Deviation17.10
Sample Variance292.28
Range77.3862
R-Value0.05
Mean Square Error314.09
R-Squared0
Significance0.87
Slope0.18
Total Sum of Squares4,092

Immix Ev To Free Cash Flow History

2024 -9.42
2023 -8.97
2022 -2.28
2021 -18.55
2020 -79.66

About Immix Biopharma Financial Statements

Immix Biopharma investors use historical fundamental indicators, such as Immix Biopharma's Ev To Free Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immix Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EV To Free Cash Flow(8.97)(9.42)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.